Bicara Therapeutics Inc.
Bicara Therapeutics Inc.
Bicara Therapeutics Inc. (BCAX) — SEC Financial Statements & Analysis
Bicara Therapeutics Inc. (BCAX) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nonrelated Party | 6 | 6 | 1 | -0 | 2 | 4 | 2 | |||||
Related Party | 6 | 6 | 1 | -0 | 2 | 4 | 2 | |||||
Assets | ||||||||||||
Assets Current | ||||||||||||
Cash And Cash Equivalents At Carrying Value | 323 | 97 | 172 | 437 | 462 | 490 | 521 | |||||
Prepaid Expense And Other Assets Current | 5 | 7 | 7 | 8 | 9 | 13 | 1 | |||||
Short Term Investments | - | 318 | 118 | - | - | 0 | - | |||||
Marketable Securities Current | 216 | - | - | - | - | - | - | |||||
Assets Current | 545 | 422 | 297 | 444 | 471 | 503 | 522 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 1 | 2 | 2 | 2 | 1 | 1 | 0 | |||||
Long Term Investments | - | - | 117 | - | - | - | - | |||||
Other Assets Noncurrent | 7 | 7 | 8 | 7 | 7 | 7 | 2 | |||||
Assets | 554 | 431 | 425 | 454 | 478 | 510 | 524 | |||||
Liabilities And Stockhold… | ||||||||||||
Liabilities Current | ||||||||||||
Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Accrued Liabilities Current | - | - | - | - | - | 13 | - | |||||
Liabilities Current | 39 | 29 | 21 | 17 | 19 | 18 | 14 | |||||
Operating Lease Liability Noncurrent | 0 | 1 | 1 | 1 | 0 | 0 | 0 | |||||
Liabilities | 40 | 30 | 22 | 18 | 19 | 18 | 15 | |||||
Stockholders Equity | ||||||||||||
Other Liabilities Noncurrent | - | - | - | - | - | 0 | 0 | |||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 929 | 760 | 724 | 720 | 717 | 713 | 710 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | - | - | - | 0 | 0 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | 0 | -0 | - | - | 0 | - | |||||
Retained Earnings Accumulated Deficit | -415 | -359 | -322 | -285 | -258 | -221 | -200 | |||||
Stockholders Equity | 514 | 401 | 403 | 435 | 459 | 492 | 510 | |||||
Liabilities And Stockholders Equity | 554 | 431 | 425 | 454 | 478 | 510 | 524 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Seed Series Redeemable Convertible Preferred Stock | - | - | - | - | - | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Series B Redeemable Convertible Preferred Stock | - | - | - | - | - | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Series C Redeemable Convertible Preferred Stock | - | - | - | - | - | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | |||||
Temporary Equity Shares Authorized | - | - | - | - | - | - | 0 | |||||
Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | |||||
Common Stock Shares Issued | 66 | 57 | 55 | 55 | 55 | 54 | 54 | |||||
Shares Outstanding | 66 | 57 | 55 | 55 | 55 | 54 | 54 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.74% | 26.53% | - | - | - | - | - | - | - | - | - | - |
| 2025 | -11.81% | -30.75% | -19.25% | 15.19% | 62.75% | 55.21% | 30.65% | 17.59% | 20.60% | 18.96% | 13.87% | 22.01% |
| 2024 | - | - | - | - | - | - | -5.59% | -25.32% | -43.53% | -9.25% | 7.99% | -19.10% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data